Unlock instant, AI-driven research and patent intelligence for your innovation.

Method and System for Treatment of Biological Tissue

a biological tissue and treatment method technology, applied in the field of biological tissue treatment methods, can solve the problems of abnormal wall motion, myocardial cell death, and myocardial tissue that is no longer receiving adequate blood flow, and achieves the effects of promoting tissue survival, promoting tissue survival, and promoting neovascularization and regeneration

Inactive Publication Date: 2014-03-27
CORMATRIX CARDIOVASCULAR INC
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides pharmacological compositions and extracellular matrix (ECM) compositions that can promote the growth and regeneration of damaged cardiovascular tissue. This approach offers advantages over prior methods and systems, including improved methods for delivering these compositions directly to damaged tissue. Ultimately, the invention aims to provide a more effective treatment for damaged cardiac tissue.

Problems solved by technology

A myocardial infarction (a common presentation of ischemic heart disease) often occurs when a coronary artery becomes occluded and can no longer supply blood to the myocardial tissue, thereby resulting in myocardial cell death.
When a myocardial infarction occurs, the myocardial tissue that is no longer receiving adequate blood flow ultimately dies (without effective intervention) and is eventually replaced by scar tissue.
Within seconds of a myocardial infarction, the under-perfused myocardial cells no longer contract, leading to abnormal wall motion, high wall stresses within and surrounding the infarct, and depressed ventricular function.
As one can readily appreciate, there are numerous incumbent risks associated with the noted methods.
Another reason is the risk of systemic toxicity which can, and in many instances will, occur with doses of pharmacological agents that are typically required to achieve desired drug concentrations in the effected cardiovascular tissue.
However, to date, cell therapy of effected cardiovascular tissue has not reached its full potential, due, in part, to the failure of implanted cells to survive and regenerate the damaged tissue in ischemic area(s) or regions with inadequate vascularization.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and System for Treatment of Biological Tissue
  • Method and System for Treatment of Biological Tissue

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0149]Five (5) porcine hearts were obtained from young calves. After removal, the hearts were stored in a saline bath.

[0150]A first heart was removed from the bath. The thickness of the heart wall was determined to range from 4 mm to greater than 2 cm with an A scan ultrasound sensor.

[0151]A multi-needle injection system of the invention, such as illustrated in FIGS. 2 and 3 was provided and prepared for the injection procedure.

[0152]An ECM composition of the invention was also provided. The ECM composition comprised two components: an ECM (i.e. SIS) particulate derived from porcine intestines and a SIS gel. The SIS particulate comprised SIS material, which was cryogenically ground to a characterized particle size, and subsequently thawed and loaded into a syringe for delivery. The particulate size was in the range of 50-350 microns.

[0153]The SIS gel comprised SIS material that was cryogenically ground, subject to enzymatic digestion in acid, lyophilized, and reconstituted to a pred...

example 2

[0165]A young porcine was provided in which CHF had been induced via serial microsphere injections down the coronary arteries.

[0166]A multi-needle injection system of the invention, such as illustrated in FIGS. 2 and 3, was prepared for injection of an ECM composition of the invention.

[0167]An ECM composition, such as described in Example 1, was also provided. The composition mixture comprised approximately 4 cc of SIS gel was mixed with 6 cc of particulate SIS to derive an injectable ECM composition.

[0168]The injectable ECM composition was then transferred into the reservoirs of the injector apparatus.

[0169]The injector control system was similarly set to provide the following delivery parameters: two (2) equal pulses at 20 and 30 milliseconds and at pressures ranging from approximately 60-120 psi. The noted parameters provided an ECM composition delivery in the range of approximately 0.5-1.0 ml per pulse.

[0170]The heart of the porcine was then exposed. A B scan ultrasound sensor w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. application Ser. No. 13 / 573,569, filed on Sep. 24, 2012, which is a continuation-in-part of U.S. application Ser. No. 11 / 334,631, filed on Jan. 18, 2006, which is a continuation of application Ser. No. 12 / 371,158, filed on Feb. 13, 2009, now abandoned, which is a continuation of application Ser. No. 11 / 747,018, filed on May 10, 2007, now abandoned.FIELD OF THE INVENTION[0002]The present invention relates to methods for treating biological tissue. More particularly, the present invention relates to methods and systems for treating damaged and diseased biological tissue; particularly, cardiovascular tissue.BACKGROUND OF THE INVENTION[0003]Myocardial infarction is a common presentation of ischemic heart disease / coronary artery disease. The World Health Organization estimated in 2004 that 12.2% of worldwide deaths occurred as a result of ischemic heart disease. Ischemic heart disease was also deemed t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/34A61K31/7056A61K31/7048A61K45/06A61K31/43A61K31/65A61K31/505A61K38/14A61K31/165A61K31/4174
CPCA61K35/34A61K31/165A61K31/7056A61K31/7048A61K45/06A61K31/43A61K31/65A61K31/505A61K38/14A61K31/4174A61K9/0019A61K48/00A61L27/367A61L27/3683A61L27/3873A61L2400/06A61L2430/20A61K31/22A61K31/366A61K31/40A61K31/404A61K31/4418A61K31/47A61K31/722A61B17/205A61B2017/00247A61L27/3633A61P43/00A61P9/00A61P9/10A61L27/3804A61L27/3834A61K2300/00A61K35/38
Inventor MATHENY, ROBERT G.
Owner CORMATRIX CARDIOVASCULAR INC